Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Edward W. Richmond who wrote (412)	1/17/1999 6:32:00 PM
From: Ian@SI	Read Replies (2) \| Respond to of 1321

Nice plug for Photofrin on the local Toronto CTV News (6PM program) from both the patient treated for Esophogeal cancer and the doctor. While the benefits of Photodynamic therapy were described, QLT wasn't explicitly mentioned, just its product.

To: Edward W. Richmond who wrote (412)	1/17/1999 7:52:00 PM
From: John McCarthy	Read Replies (1) \| Respond to of 1321

Edward ... I am long qlt. I am at the same place you are at with respect to competition. <<The company that is first to market usually wins the game>> It is my understanding that the equip. goes for about $40 Grand. Once buyers expend $40 grand, there's no going back unless a competitors product is significantly better than visudyne. All things being equal ... comparable performance will be a tough marketing sell. On the other hand, if a competitor shows better performance .... no doubt there will be one hell of a marketing dogfight. Just my opinion. regards, John McCarthy